Table 1.
Clinical trials of epigenetic agents combined with immune checkpoint inhibitors for cancer therapy.
| Identifier | Malignant Conditions | Therapeutics (Single or Combined) |
Start Date | Results |
|---|---|---|---|---|
| NCT02608268 | Advanced solid tumors | 1. MBG453 (Tim3 antibody) 2. PDR001 (PD-1 antibody) 3. Decitabine |
November 2015 | Recruiting |
| NCT03066648 | Acute myeloid leukemia or high risk myelodysplastic syndrome |
1. Decitabine/Azacytidine 2. PDR001 3. MBG453 |
July 2017 | Recruiting |
| NCT03019003 | Head and neck cancer | 1. ASTX 727 (oral decitabine) 2. Durvalumab (PD-L1 antibody) |
March 2017 | Recruiting |
| NCT03161223 | Relapsed or refractory peripheral T-cell lymphomas (PTCL) |
1. Durvalumab (PD-L1 inhibitor) 2. Romidepsin 3. 5-azacytidine 4. Pralatrexate |
May 2018 | Recruiting |
| NCT01928576 | Non-small cell lung cancer (NSCLC) | 1. Azacytidine 2. Entinostat 3. Nivolumab |
August 2013 | Recruiting |
| NCT04611711 | PD-1 monoclonal antibody-resistant digestive system tumors | 1. Decitabine 2. TQB2450 (PD-1 inhibitor) 3. Anlotinib (VEGFR inhibitor) |
November 2020 | Recruiting |
| NCT02890329 | Relapsed or refractory myelodysplastic syndrome or acute myeloid leukemia | 1. Decitabine 2. Ipilimumab (CTLA-4 antibody) |
September 2016 | Recruiting |
| NCT04277442 | Newly diagnosed TP53 mutated acute myeloid leukemia | 1. Decitabine 2. Nivolumab (PD-1 inhibitor) 3. Venetoclax (Bcl-2 inhibitor) |
February 2020 | Recruiting |
| NCT02397720 | Refractory/relapsed or newly diagnosed acute myeloid leukemia | 1. Azacytidine 2. Ipilimumab 3. Nivolumab |
April 2015 | Recruiting |
| NCT02816021 | Metastatic melanoma | 1. Azacytidine 2. Pembrolizumab (PD-1 inhibitor) |
February 2017 | Recruiting |
| NCT03233724 | Inoperable locally advanced or metastatic NSCLC, and esophageal carcinomas, or pleural mesotheliomas |
1. Oral decitabine 2. Tetrahydrouridine (inhibitor of cytidine deaminase) 3. Pembrolizumab (PD-1 inhibitor) |
April 2018 | Recruiting |
| NCT02959437 | Advanced solid tumors and previously treated stage IIIB or stage IV non-small cell lung cancer and stage IV microsatellite-stable colorectal cancer | 1. Azacytidine 2. Pembrolizumab 3. Epacadostat (indoleamine2,3-dioxygenase inhibitor) 4. INCB057643 (BET inhibitor) 5. INCB059872 (LSD1 inhibitor) |
February 2017 | Recruiting |
| NCT02546986 | Locally advanced or metastatic non-small cell lung cancer | 1. CC-486 (oral azacytidine) 2. Pembrolizumab |
October 2015 | Recruiting |
| NCT04250246 | Melanoma and NSCLC resistant to anti-PD1/PDL1 | 1. Ipilimumab + Nivolumab + Guadecitabine 2. Ipilimumab + Nivolumab |
March 2020 | Recruiting |
| NCT03765229 | Melanoma | 1. Entinostat 2. Pembrolizumab |
March 2019 | Recruiting |
| NCT02437136 | NSCLC, melanoma and mismatch repair-proficient colorectal cancer |
1. Entinostat 2. Pembrolizumab |
July 2015 | Recruiting |
| NCT03024437 | Advanced renal cell carcinoma | 1. Atezolizumab (PD-L1 inhibitor) 2. Bevacizumab (VEGF inhibitor) 3. Entinostat |
May 2017 | Recruiting |
| NCT04708470 | Solid tumors, metastatic checkpoint refractory HPV-associated tumors, microsatellite stable colon cancer | 1. Bintrafusp Alfa (bifunctional fusion protein composed of the extracellular domain of the TGF-β receptor II fused to an IgG1 antibody blocking PD-L1) 2. NHS-IL12 3. Entinostat |
August 2021 | Recruiting |
| NCT02915523 | Advanced epithelial ovarian cancer | 1. Entinostat 2. Avelumab (PD-L1 inhibitor) |
January 2017 | Recruiting |
| NCT03250273 | Previously treated unresectable/metastatic cholangiocarcinoma and pancreatic cancer | 1. Entinostat 2. Nivolumab |
November 2017 | Recruiting |
| NCT03854474 | Locally advanced and metastatic urothelial carcinoma | 1. Pembrolizumab 2. Tazemetostat (EZH2 inhibitor) |
May 2019 | Recruiting |
| NCT02453620 | Unresectable or locally advanced or metastatic Her2-negative breast cancer | 1. Entinostat 2. Ipilimumab 3. Nivolumab |
November 2015 | Recruiting |
| NCT02395627 | Hormone receptor expressing advanced breast cancer | 1. Vorinostat 2. Tamoxifen 3. Pembrolizumab |
May 2015 | Recruiting |